Drugs / Yellow Fever
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01488890 | Dec 2011 → Sep 2013 | Dengue hemorrhagic fever, yellow fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03180359 | Jan 2016 → Oct 2019 | disease related to transplantation | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yellow Fever | “* Yellow Fever” NCT03180359 ↗ |
| Modality | Vaccine | “Participants received single dose of YF vaccine at Day 0.” NCT01488890 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT01488890 ↗ |